Blueprint Medicines’ BLU-667 drug has shown promising activity and disease control as a highly selective RET inhibitor. Credit: The University of Texas MD Anderson Cancer Center.

Blueprint Medicines has reported positive proof-of-concept results from the ongoing ARROW clinical trial, a Phase I open-label study of BLU-667 to treat patients with RET-altered solid tumours.

The ARROW trial aims to analyse the safety and tolerability of BLU-667 in multiple ascending doses in adults with RET-altered Non-Small Cell Lung Cancer (NSCLC), Medullary thyroid cancer (MTC) and other advanced solid tumours.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It features a dose escalation portion and an expansion portion.

Results from the dose escalation portion of the trial demonstrated improved clinical activity for once-daily (QD) dosing of BLU-667 across multiple tumour types and RET genotypes, including in patients whose disease had progressed on prior multi-kinase inhibitor therapy.

“The safety, clinical activity and pharmacodynamic results from the dose escalation portion of the Phase I ARROW trial demonstrate compelling proof-of-concept for BLU-667.”

Until the data cut-off date of 6 April, the results demonstrated radiographic tumour reductions in 84% of patients with RET-altered solid tumours with measurable target lesions.

In patients evaluable for response, preliminary overall response rates (ORR) were found to be 50% in patients with NSCLC and 40% in patients with MTC.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

From the data cut-off date, once-daily (QD) dosing of BLU-667 was reportedly well-tolerated, and investigators recorded Grade 1 or 2 most adverse events (AEs) during the dose-escalation portion of the trial that involved the treatment of 53 patients.

Blueprint has completed patient enrolment in this phase and started enrolling patients for the expansion portion of the trial.

Objectives of the ARROW trial include evaluating response, pharmacokinetics, pharmacodynamics and safety.

Blueprint Medicines chief medical officer Andy Boral said: “The data announced today reveal the broad clinical potential of BLU-667, a potent and highly selective RET inhibitor, and further demonstrate the power and reproducibility of Blueprint Medicines’ proprietary drug discovery platform.

“We believe the safety, clinical activity and pharmacodynamic results from the dose escalation portion of the Phase I ARROW trial demonstrate compelling proof-of-concept for BLU-667.”

The University of Texas MD Anderson Cancer Center has led the ARROW trial.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact